Swiss Life Asset Management Ltd Raises Position in Zoetis Inc. $ZTS

Swiss Life Asset Management Ltd boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 11.3% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 145,691 shares of the company’s stock after buying an additional 14,744 shares during the period. Swiss Life Asset Management Ltd’s holdings in Zoetis were worth $21,318,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in the business. Halbert Hargrove Global Advisors LLC raised its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after buying an additional 144 shares during the last quarter. KERR FINANCIAL PLANNING Corp purchased a new stake in Zoetis during the third quarter valued at approximately $31,000. Financial Consulate Inc. bought a new position in Zoetis in the third quarter worth approximately $39,000. SJS Investment Consulting Inc. boosted its stake in shares of Zoetis by 1,606.3% during the 3rd quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after acquiring an additional 257 shares during the last quarter. Finally, TruNorth Capital Management LLC bought a new stake in shares of Zoetis during the 3rd quarter valued at $42,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.1%

Shares of NYSE ZTS opened at $116.03 on Friday. The company has a 50 day simple moving average of $124.58 and a 200-day simple moving average of $130.88. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. The company has a market capitalization of $48.98 billion, a P/E ratio of 19.27, a P/E/G ratio of 1.79 and a beta of 0.95. Zoetis Inc. has a 1 year low of $114.47 and a 1 year high of $172.23.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.8%. Zoetis’s payout ratio is 35.22%.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on ZTS shares. Bank of America lifted their target price on Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Weiss Ratings raised Zoetis from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, March 12th. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price objective (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. KeyCorp assumed coverage on Zoetis in a report on Thursday, November 20th. They set a “sector weight” rating for the company. Finally, HSBC set a $140.00 price objective on Zoetis in a report on Wednesday, December 10th. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.